Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme agrees research deal with BioRelix

Merck Sharpe and Dohme agrees research deal with BioRelix

6th October 2010

Merck Sharpe and Dohme has agreed to work with the anti-infective drug specialist BioRelix in a new collaboration focusing on antibacterial candidates.

The agreement will see Merck Sharpe and Dohme provide an upfront fee and research funding for BioRelix to identify compounds with potential activity against a number of key bacterial targets.

This research will utilise BioRelix's proprietary riboswitch technology platform and is expected to create new options against difficult-to-treat and drug-resistant infections.

Both companies will be involved in undertaking preclinical programmes for the compounds, with Merck Sharpe and Dohme taking charge of evaluating the treatments for possible further development.

Dr Roger Pomerantz, senior vice-president and global franchise head for infectious diseases at Merck Research Laboratories, said: "Collaborations with companies like BioRelix are essential as we seek to apply the latest innovative drug discovery technologies towards the discovery of new much-needed antibacterial medications."

Earlier this week, Merck Sharpe and Dohme returned international marketing rights for the cancer drug Caelyx to Janssen, following the expiry of an agreement from 1996.ADNFCR-8000103-ID-800101096-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.